ACA
IOVA icon

Avoro Capital Advisors’s Iovance Biotherapeutics IOVA Stock Holding History

Avoro Capital Advisors’s Portfolio IOVA Stock Details IOVA Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-3,500,000
Closed -$25.9M – 36
2024
Q4 		$25.9M Sell
3,500,000
-740,000
-17% -$6.86M 0.37% 32
2024
Q3 		$39.8M Sell
4,240,000
-7,460,000
-64% -$70.7M 0.58% 28
2024
Q2 		$93.8M Hold
11,700,000
– – 1.25% 20
2024
Q1 		$173M Buy
11,700,000
+5,000,000
+75% +$58.2M 2.02% 17
2023
Q4 		$54.5M Hold
6,700,000
– – 0.75% 22
2023
Q3 		$30.5M Hold
6,700,000
– – 0.48% 25
2023
Q2 		$47.2M Sell
6,700,000
-320,000
-5% -$2.29M 0.64% 24
2023
Q1 		$42.9M Hold
7,020,000
– – 0.64% 22
2022
Q4 		$44.9M Sell
7,020,000
-2,000,000
-22% -$15.6M 0.67% 24
2022
Q3 		$86.4M Sell
9,020,000
-200,000
-2% -$2.31M 1.6% 17
2022
Q2 		$102M Buy
9,220,000
+95,000
+1% +$1.24M 2.01% 14
2022
Q1 		$152M Buy
9,125,000
+450,000
+5% +$6.96M 2.77% 14
2021
Q4 		$166M Buy
8,675,000
+175,000
+2% +$3.85M 2.82% 11
2021
Q3 		$210M Sell
8,500,000
-600,000
-7% -$14.1M 3.29% 8
2021
Q2 		$237M Buy
9,100,000
+1,100,000
+14% +$28.6M 4.12% 8
2021
Q1 		$253M Buy
8,000,000
+500,000
+7% +$20.7M 4.37% 8
2020
Q4 		$348M Sell
7,500,000
-2,036,039
-21% -$80.8M 5.99% 4
2020
Q3 		$314M Sell
9,536,039
-825,000
-8% -$25.3M 4.46% 4
2020
Q2 		$284M Buy
10,361,039
+1,350,626
+15% +$44.4M 5.62% 4
2020
Q1 		$270M Buy
9,010,413
+184,374
+2% +$4.89M 9.1% 3
2019
Q4 		$244M Sell
8,826,039
-1,775,000
-17% -$40.4M 7.17% 4
2019
Q3 		$193M Sell
10,601,039
-151,546
-1% -$3.35M 8.05% 3
2019
Q2 		$264M Buy
10,752,585
+221,723
+2% +$3.34M 9.11% 3
2019
Q1 		$100M Buy
10,530,862
+269,823
+3% +$2.62M 4.33% 10
2018
Q4 		$90.8M Buy
10,261,039
+1,598,319
+18% +$15.4M 5.43% 7
2018
Q3 		$97.5M Buy
8,662,720
+485,000
+6% +$6.88M 4.48% 8
2018
Q2 		$105M Buy
8,177,720
+99,215
+1% +$1.45M 4.03% 8
2018
Q1 		$137M Buy
8,078,505
+2,825,055
+54% +$42.8M 6.52% 4
2017
Q4 		$42M Buy
5,253,450
+1,052,107
+25% +$8.45M 2.72% 15
2017
Q3 		$32.6M Buy
4,201,343
+50,000
+1% +$316K 2.53% 16
2017
Q2 		$30.5M Sell
4,151,343
-400,000
-9% -$2.54M 3.85% 10
2017
Q1 		$33.9M Buy
4,551,343
+30,700
+0.7% +$225K 4.33% 8
2016
Q4 		$31.4M Buy
4,520,643
+263,296
+6% +$1.81M 6.35% 4
2016
Q3 		$35M Sell
4,257,347
-81,210
-2% -$687K 6.15% 3
2016
Q2 		$35.1M Buy
4,338,557
+1,213,359
+39% +$7.62M 7.81% 2
2016
Q1 		$15.9M Sell
3,125,198
-62,409
-2% -$342K 5.54% 7
2015
Q4 		$24.6M Buy
3,187,607
+6,694
+0.2% +$46.5K 8.48% 3
2015
Q3 		$18.3M Buy
3,180,913
+257,848
+9% +$2.01M 4.76% 8
2015
Q2 		$26.8M Buy
2,923,065
+773,158
+36% +$8.63M 7.38% 4
2015
Q1 		$26M Buy
+2,149,907
New +$24.2M 9.99% 2

Other funds holding IOVA

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
MFM
MHR Fund Management New York $1.37B AUM 68.35% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
LFCM
Long Focus Capital Management San Juan, Puerto Rico $3.8B AUM 7.31% 1-Year Est. Return
HRCM
Hood River Capital Management Palm Beach Gardens, Florida $9.98B AUM 145.42% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
UBS AM
UBS AM Chicago, Illinois $481B AUM 26.39% 1-Year Est. Return

Avoro Capital Advisors's IOVA Position: Q1 2025 in Review

Avoro Capital Advisors sold out of Iovance Biotherapeutics (IOVA) in Q1 2025, closing a stake of 3,500,000 shares — an estimated $25.9M sold.

Avoro Capital Advisors first reported a position in IOVA in Q1 2015 and held it in 40 quarters. The position peaked at $348M in Q4 2020. 301 funds tracked by Wall St. Rank hold IOVA as of Q1 2025.

  • Avoro Capital Advisors reported no remaining Iovance Biotherapeutics position as of Q1 2025 after selling out during the quarter.
  • Avoro Capital Advisors sold 3,500,000 Iovance Biotherapeutics shares in Q1 2025, an estimated $25.9M.
  • Avoro Capital Advisors first reported a position in Iovance Biotherapeutics in Q1 2015 and held it in 40 quarters.
  • Avoro Capital Advisors's Iovance Biotherapeutics position peaked at $348M in Q4 2020.
  • 301 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q1 2025.

Based on Avoro Capital Advisors's 13F filing for Q1 2025, filed 15 May 2025.